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Transdermal Permeability of N-Acetyl-D-Glucosamine
Transdermal Permeability of NAGSolomon T. Garner, Jr., Bridg´ette J. Israel, Hishamaldin Achmed, and Anthony C. Capomacchia
Department of Pharmaceutical and Biomedical Sciences, The University of Georgia, Atlanta, GA 
Trina Abney and Parastoo Azadi
The University of Georgia, Complex Carbohydrate Center, Athens, GA 
Transdermal permeation of N-acetyl-D-glucosamine (NAG),
a metabolite of glucosamine was examined. Glucosamine salts are
nutraceuticals used in the oral treatment of osteoarthritis. Sparse
information is available regarding glucosamine and NAG trans-
dermal or percutaneous transport and absorption. Permeability of
NAG in various enhancer suspensions was evaluated by using
shed snakeskin as a model membrane via Franz-type cell diffu-
sion studies. Negligible permeability was observed for NAG in
neat solutions of known membrane permeation enhancers ethanol,
oleic acid, isopropyl myristate, and isopropyl palmitate, as well as
from saturated solutions of NAG in water or phosphate buffer.
Permeability measurements obtained from saturated solutions of
NAG in DMSO and phosphate buffer solutions containing etha-
nol at 2%, 5%, 10%, 25%, and 50% demonstrated excellent per-
meation. Permeability coefficients of the phosphate buffer/
ethanol solutions at 5%, 10%, and 25% were about threefold
larger in value as those for saturated DMSO solution, whereas the
2% and 50% solution values were lower.
Keywords N-acetyl-D-glucosamine (NAG), glycosaminoglycan
(GAG), osteoarthritis, transdermal permeation, skin
permeation enhancers
BACKGROUND
The oral use of glucosamine supplements became
popular after being featured in the book, The Arthritis
Cure by Jason Theodasakis, MD.[1] Currently, gluco-
samine and its metabolites are not classified as drugs but
as nutraceutical/dietary supplements under United States
Food and Drug Administration’s Dietary Supplement
Health and Education Act of 1994 (DSHEA). Oral dosage
formulations of N-Acetyl-D-glucosamine (NAG) and its
parent compound glucosamine in salt form (sulfate, hydro-
chloride, etc.) are commercially available nutraceuticals
and are commonly administered in conjunction with chon-
droitin sulfate, also a readily available nutraceutical. Glu-
cosamine and chondroitin have been reported effective in
the oral treatment of osteoarthritis but have not undergone
the rigorous studies needed for FDA approval as pharma-
ceuticals.[1,2] The National Institutes of Health (NCCAM)
(Bethesda, MD, USA) has an ongoing multicenter study—
GAIT (Glucosamine/Chondroitin Arthritis Intervention
Trial), which has evaluated the efficacy of orally adminis-
tered glucosamine and chondroitin oral supplements. Pub-
lished study results indicate that a combination of
glucosamine and chondroitin might be most effective in
patients with osteoarthritis with moderate to severe pain
and in many cases obviates the need for NSAID use.[3]
Glucosamine and chondroitin salts are charged,
highly polar, aqueous soluble, and apparently poor candi-
dates for transdermal absorption. Currently, there are topi-
cal products containing these salts, and other ingredients,
marketed as nutraceuticals for the treatment of osteoarthri-
tis. NAG, an acetylated glucosamine metabolite, is less
polar, uncharged, and appears to be a more likely candi-
date for transdermal or percutaneous absorption.
Glucosamine and its orally delivered salt forms are
metabolized to NAG via the hexosamine pathway; glu-
cosamine or galactosamine, plus a uronic acid, is incorpo-
rated as a disaccharide unit into all macromolecules requiring
amino sugars, such as keratan sulfates, dermatan sulfates,
chondroitin 4- and 6-sulfates, hyluronates, and heparin and
heparan sulfates, to produce glycosaminoglycans (GAGs).
GAGs are highly negatively charged molecules, with an
extended conformation, that demonstrate high viscosity and
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low compressibility—ideal as a lubricating fluid for anatomi-
cal joints. The majority of GAGs in the body are linked to
core proteins to form proteoglycans or mucopolysaccarides,
which are basic components of skin, tissue, and cartilage.[4,5]
INTRODUCTION
The study objectives were to evaluate stratum cor-
neum permeability of NAG with use of shed snakeskin
and to assess the feasibility of pursuing a percutaneous
formulation for local therapy to osteoarthritic joints. In
this connection, a provisional patent application, followed
by patent application 235.00560201 was filed with the
U.S. Patent and Trademark Office.[6] Permeability was
evaluated by using NAG solutionss of various known
membrane transport-enhancing reagents, ethanol, oleic
acid, isopropyl myristate, and isopropyl palmitate; NAG
solutions of water, phosphate buffer, phosphate buffer,
and aqueous ethanol; and NAG saturated DMSO solution.
Oral administration of glucosamine, its salts, and
NAG are affected by the liver’s first-pass metabolism.[7]
However, a more recent report indicates that these agents
may be metabolized mostly in the gut rather than solely by
the liver.[8] Few pharmacokinetic literature reports exist on
the disposition of these agents in articular cartilage. Setni-
kar et al. reported on the pharmacokinetic properties of
glucosamine in dogs and man.[9,10] It is estimated that
approximately 87% of the original glucosamine oral dose
is absorbed and excreted; <13% is widely distributed in
the body; and <<1% reaches osteoarthritic joints. Chon-
droitin is known to degrade into its basic dissaccaride
components within the gut prior to further metabolism.[11]
Although only a small fraction of glucosamine reaches the
articular cartilage target site, it is reported to exhibit a high
potency; and together glucosamine and chondroitin ther-
apy demonstrate therapeutic efficacies over time.[2] NAG
was selected because it is an active metabolite and prodrug
of glucosamine and, owing to its commercial availability,
relatively low cost and stability. It possesses the following
physical and chemical characteristics, making it a reason-
able candidate for transdermal delivery and percutaneous
absorption: 1) high potency, 2) reasonably lipid soluble, 3)
low molecular weight, 4) unique biochemical pathway
with active transport from blood into articular cartilage.[5]
MATERIALS AND METHODS
Chemicals
NAG, 99.9% purity was purchased from MP Biomed-
ical (Aurora, OH). All enhancer reagents purchased for
this study were 99.9+% pure. All other reagents were of
analytical grade and used without further purification.
Analysis
NAG analysis was carried out by using high-
performance anion exchange chromatography with
pulsed amperometric detection (HPAE-PAD); Dionex,
Sunnyvale, CA, USA): Dionex DX-500 HPLC system
consisting of a GP40 gradient pump, ED40 Electro-
chemical detector, AS3500 autosampler and PeakNet
Chromatography Workstation.[1215] The HPAE-PAD
was equipped with CarboPac™ PA20 (3 × 150 mm),
analytical anion-exchange column for the rapid, high-
resolution separation of monosaccharides and disaccha-
rides, using pulsed amperometric detection,[12–15] a CarboPac
PA20 analytical guard column (3 × 30 mm), and a
carbonate trap column (25 × 15 mm). Mobile phase (A)
was degassed and deionized water. Mobile phase (B)
consisted of 0.02 N NaOH prepared with deionized
water and filtered with 0.45-μm filters in a solvent filtra-
tion apparatus (Waters-Millipore, Milford, MA, USA)
that was degassed under vacuum. The mobile phase sys-
tem was run at a gradient concentration of 16 mM
NaOH at a flow rate of 0.5 mL/min. A standard calibra-
tion curve of NAG (Figure 1) was obtained with linear
regression and value of R2 = 0.9934 in 0.1 M phosphate
buffer at pH 7.4. Each sample set was run with external
standards. The sample concentration values were obtained
via the Peak Net software. These values were compared
with to those obtained by calculations of the peak area
and peak height observed as functions of the standard
curve linear regression equation. The instrument LOD
(limit of detection) was 0.05 ng/mL.
Figure 1. Standard calibration curve of NAG (R2 = 0.9934)
obtained in 0.1M phosphate buffer at pH 7.4.
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In Vitro Membrane Permeation
Shed snakeskins were used as a model membrane
for all permeation studies using the NAG solutions in
known membrane permeation enhancers; ethanol, oleic
acid, isopropyl myristate, and isopropyl palmitate; satu-
rated solutions of NAG in water and in phosphate
buffer; as well as in DMSO solution (Table 1; Figure 2)
and phosphate buffer containing ethanol at 2%, 5%,
10%, 25%, and 50% solutions (Table 2; Figure 3). The
skins were stored at 20°C before use; a piece of the dor-
sal section was trimmed to fit the Franz cell and
hydrated at 37°C for 30 min.[16] Franz-cell diffusion
experiments were carried out. For experiments using
ethanol, oleic acid, isopropyl myristate, isopropyl palm-
itate, DMSO, and phosphate buffer containing ethanol at
2%, 5%, 10%, 25%, and 50% solutions in the donor
phase, receptor cells were filled with 7.4 pH 0.1 M phos-
phate buffer, and the donor cell was filled with the cor-
responding NAG solution. Receptor solutions were
maintained at 37°C and stirred with a magnetic stirrer.
The snakeskins were mounted between the receptor and
donor cells. The surface exposed to diffusion was 2.54
cm2 (diameter 1.8 cm) and the receptor cell volume was
6 cm3. The donor cell was covered with plastic film. The
system was allowed to equilibrate at 37°C for 2 hr
before each experiment. To the donor cells, 5 mL of the
NAG-enhancer solution (100 mg/mL) maintained at
37°C were added. Samples were taken at intervals over a
24-hr period, 200-μL samples of receptor solutions were
taken and replaced with fresh buffer; experiments were
conducted in triplicate. The amounts of NAG that per-
meated through the snakeskin were determined by
HPAE-PAD.
Data Treatment
Permeation was determined from the increasing
amount of NAG in the receptor medium, and cumulative
steady-state permeation from plots of cumulative amount
of NAG, per unit area (μg/cm2) that permeated through the
snakeskin versus time (Figures 2 and 3); where the slope
of the linear portion of the plot was used to calculate the
steady-state flux, Jss; μg/cm2/h.[16–18] NAG permeability
coefficients (kp) were calculated from the expression kp =
Jss × ΔC, where Jss, and ΔC are the flux and concentration
change, respectively (Tables 1 and 2). Permeation was
rapid with almost no lag time observed for NAG in DMSO
(Figure 2; Table1)[20]; and also for permeation of the etha-
nol-laced phosphate buffer solutions of NAG after exami-
nation of the intersection of the linear portion of the plots
with the x-axis (Figure 3; Table 2).
Table 1 
Physiochemical data obtained for the permeation of 
N-acetylglucosamine (NAG) through shed snake skin using 
dimethyl sulfoxide (DMSO) solution in the donor phase and pH 
7.4 phosphate buffer in receptor phase (from Figure 2)
Parameter
Jss (μg/cm2/hr) 8.28
Cumulative 24-hr steady-state 
permeation (μg)
510.5
Permeation coefficient, kp (cm/hr) × 103 0.425
% NAG in receptor phase after 24 hr 2.57
Figure 2. N-acetylglucosamine (NAG) permeation through
shed snakeskin at 37.5°C (cumulative concentration vs. time) in
DMSO solution (100 mg/mL). Each point represents the mean ± D,
n = 3.
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Table 2 
Physicochemical data obtained for the permeation of N-acetylglucosamine (NAG) through shed snake skin via phosphate buffer 
containing ethanol at 2%, 5%, 10%, 25%, and 50% solutions in the donor phase and pH 7.4 phosphate buffer in the receptor phase
% Ethanol, enhancing agent 2 5 10 25 50
Jss (μg/cm2/hr); from linear portion 
of curves in Figure 3
6.88 26.8 29.5 25.5 5.14
Cumulative 24-hr permeation (μg) 196 572.8 572.1 482.6 54.0
Permeation coefficient kp (cm/hr) × 103 0.347 1.38 1.52 1.31 0.264
% NAG in receptor phase after 24 hr 0.98 2.89 2.88 2.44 0.273
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Determination of Partition Coefficients
The oil/water partition coefficient for NAG was deter-
mined by using n-octanol/phosphate buffer (pH 5.5, 6.5,
and 7.4 at 0.1 M) and n-octanol/water (Table 3).[19] In each
case 5 mL of n-octanol was mixed with 5 mL of aqueous
solutions containing NAG and shaken at 37°C for 24 hr.
The mixture was centrifuged, and the organic and aqueous
phases were separated. NAG concentration in the filtrates
was determined by HPAE-PAD after appropriate dilution.
RESULTS AND DISCUSSION
Initial permeability investigations were carried out by
using shed snakeskin as a model membrane to human skin,
a widely recognized model for preliminary studies due to
its similarity in composition to the human stratum cor-
neum.[20,21] Negligible NAG transport was observed from
neat saturated solutions of the membrane permeability
enhancers; pure ethanol, oleic acid, isopropyl myristate,
and isopropyl palmitate. No permeation was observed
from the aqueous saturated solutions of NAG in water or
phosphate buffer solutions (pH 5.5, 6.5, and 7.4; 0.1 M).
This indicates that permeation of NAG probably does not
involve interactions with intercellular lipids as presented
in Barry’s lipid-protein partitioning theory.[18,22] Partition
coefficients are contained in Table 3; the NAG oil-water
partition coefficient is shown to increase concomitantly
with the increase in buffer solution pH, no doubt owing to
the greater concentration of unionized species at pH values
greater than the pKa of 6.73 (Table 3). The theoretically
calculated permeation coefficient (kp) of 1.9 × 10−4 is sim-
ilar in magnitude to those we report in Tables 1 and 2.
DMSO was chosen for evaluation as a benchmark
permeation enhancer due to its physical properties and
well-documented enhancement properties.[22] Enhancers
in the category of DMSO (also ethanol) are reported to
disrupt intercellular lipids of the stratum corneum by
increasing a drug’s partitioning into the stratum corneum
with a concomitant increase in drug permeation through
the intercellular junctions.[23–25] From the plot containing
cumulative NAG concentration per unit area (μg/cm2) ver-
sus time, NAG’s in vitro flux was 8.28 μg/cm2 (Figure 2;
Table 1). The assumption is that NAG’s high polarity and
low partition coefficient (Table 3) contributes to its perme-
ation in DMSO and poor permeability in purely aqueous
solution owing to solubility considerations. The study
shows that DMSO allows NAG to be transported immedi-
ately and continuously as seen in Figure 2 with a linear
concentration increase over time.
NAG was also incorporated in ethanol/buffer solution
at various ethanol concentrations. Ethanol is known to
promote transdermal penetration and percutaneous absorp-
tion of many drugs.[26] NAG transdermal transport was not
observed from phosphate buffer or pure ethanol where it is
highly soluble and insignificantly soluble, respectively.
NAG permeation was observed in sink conditions from
phosphate buffer containing ethanol at 2%, 5%, 10%,
25%, and 50% (Figure 2). The cumulative concentration
of the solutions containing 5% and 10% ethanol are very
similar after 24 hr; the 25% solution slightly lower; and
the 2% and 50% ethanol in buffer solutions deliver com-
paratively less NAG. Beyond 50% ethanol concentration
in buffer, the NAG precipitated. The flux values for 5%,
10%, and 25% ethanol concentrations are also close in
value, whereas the 50% and 2% values are significantly
lower.
Figure 3. The effect of ethanol concentration on N-
acetylglucosamine (NAG; 100 mg/mL) permeation at 37.5°C
through shed snakeskin (cumulative concentration, μg/cm2, vs.
time). Each point represents the mean ± D, n = 3. 2% ethanol: ;
5% ethanol: , 10% ethanol: ▲, 25% ethanol: ❍, 50% ethanol: ×.
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Table 3 
Experimentally determined partition coefficients for N-acetyl-D-glucosamine (NAG) [pKa 6.73] in pH 
solutions 5.5, 6.0, 6.5, 7.4, and water; and permeation coefficient theoretically calculated according to Potts-Guy 
equation using our experimentally derived value for NAG Octanol/water ratio of 0.116.[15]
Octanol/pH 5.5buffer Octanol/pH 6.5 buffer Octanol/pH 7.4 buffer Octanol/water kp(cm/hr)[19]
0.085 0.089 0.110 0.116 1.9 × 10−4
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The results indicate that thermodynamic and solubil-
ity effects may control NAG permeation in DMSO at
100%, and in the different concentrations of ethanol buffer
solutions.[27] NAG in vitro flux and cumulative perme-
ations from 5%, 10%, and 25% ethanol solution were
larger in magnitude than that observed in DMSO and are
also larger than those recently reported for glucosamine
sulfate in a transdermal permeation study.[28] The results
indicate that a solution concentration of 5–25% ethanol as
an enhancer in delivery vehicles appears to be an excellent
starting point toward a percutaneous formulation of NAG.
In conclusion, DMSO is an excellent skin penetration
enhancer for NAG. DMSO is generally used in veterinary
drug delivery, and the use of DMSO in NAG formulations
may be useful for localized osteoarthritis treatment in ani-
mals because DMSO is not an FDA-approved excipient
for human use in topical or transdermal pharmaceutical
products. Results also show that ethanol enhances the per-
meation of NAG in the concentration range of 5–25%, in
shed snakeskin. This finiding indicates that formulations
containing 5–25% ethanol may enhance NAG permeation
in humans.
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